Vor Biopharma
51 hedge funds and large institutions have $571M invested in Vor Biopharma in 2021 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 11 increasing their positions, 15 reducing their positions, and 11 closing their positions.
18% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 11
4% more funds holding
Funds holding: 49 → 51 (+2)
0.01% more ownership
Funds ownership: 4.14% → 4.14% (+0.01%)
0% more funds holding in top 10
Funds holding in top 10: 5 → 5 (0)
27% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 15
56% less capital invested
Capital invested by funds: $1.31B → $571M (-$740M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$2.77M |
| 2 |
PPA
Parametric Portfolio Associates
Seattle,
Washington
|
+$2.11M |
| 3 |
PL
Parkwood LLC
Cleveland,
Ohio
|
+$1.25M |
| 4 |
NAM
Nexpoint Asset Management
Dallas,
Texas
|
+$1.23M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$908K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$3.21M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.86M |
| 3 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$1.25M |
| 4 |
ZDA
Zweig-DiMenna Associates
New York
|
-$862K |
| 5 |
JP Morgan Chase
New York
|
-$534K |
VOR Hedge Fund Activity: Q2 2021 in Review
51 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Vor Biopharma (VOR) for Q2 2021, worth a combined $571M — down 56% from $1.31B a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new VOR positions and 11 closed out — a net gain of 2 holders — while 11 added to existing stakes and 15 trimmed.
The largest buyer was Morgan Stanley, opening a new position worth an estimated $2.77M. The largest seller was Sectoral Asset Management, cutting an estimated $3.21M.
- 51 institutional investors held Vor Biopharma (VOR) as of Q2 2021, up from 49 in Q1 2021.
- Funds reported $571M of Vor Biopharma stock for Q2 2021, down 56% quarter-over-quarter.
- 13 funds opened new Vor Biopharma positions in Q2 2021 and 11 closed out, a net change of +2 holders.
- The largest Vor Biopharma buyer in Q2 2021 was Morgan Stanley, an estimated $2.77M added.
- The largest Vor Biopharma seller in Q2 2021 was Sectoral Asset Management, an estimated $3.21M sold.
Based on aggregated 13F filings for Q2 2021.